Metabolic Characteristics of Plasma OxPLs in STEMI Patients.

January 27, 2026 updated by: First Affiliated Hospital of Ningbo University

Metabolic Characteristics of Plasma OxPLs in STEMI Patients and Its Value Analysis in Predicting MACEs Risk After PCI Surgery.

The goal of this observational study is to investigate the structural composition and metabolic characteristics of OxPLs in STEMI patients. Explore OxPLs characteristic fingerprint biomarkers from different populations and analyze OxPLs fingerprint spectra. Based on the OxPLs fingerprint of STEMI patients, a machine learning classifier is used to establish an artificial intelligence assisted post PCI MACE risk prediction system, achieving the transformation of basic research into clinical application.

Study Overview

Status

Enrolling by invitation

Conditions

Study Type

Observational

Enrollment (Estimated)

240

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Zhejiang
      • Ningbo, Zhejiang, China, 315010
        • First Affiliated Hospital of Ningbo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

STEMI patients admitted to our cardiovascular department for concurrent PCI surgery between January 2025 and December 2025.

Description

Inclusion Criteria:

  • The patient meets the diagnostic criteria for STEMI (refer to the "Diagnosis and Treatment Guidelines for Acute ST Segment Elevation Myocardial Infarction (2021)")
  • Agree to perform direct PCI
  • The onset time is less than 12 hours and successfully undergoing emergency PCI treatment
  • After admission, all STEMI patients are routinely treated with antiplatelet aggregation, anticoagulation, lipid-lowering, and anti myocardial remodeling drugs.

Exclusion Criteria:

  • Previous history of myocardial infarction
  • Accompanied by other cardiovascular diseases, such as severe heart valve disease, severe heart failure, congenital heart disease, cardiomyopathy, etc
  • Merge with severe infection
  • Merge with severe anemia
  • Merge with severe liver and kidney dysfunction
  • Combined with malignant tumors
  • Accompanied by a history of autoimmune or hematological diseases
  • Recent history of severe trauma or surgery
  • Patients with incomplete clinical data
  • The patient does not agree to undergo data collection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Healthy
Healthy people
CAD
Stable coronary heart disease patient
STEMI-M
Male patients with ST segment elevation myocardial infarction
STEMI-F
female patients with ST segment elevation myocardial infarction

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Time Frame: 12 months
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

First Affiliated Hospital of Ningbo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

January 27, 2026

First Submitted That Met QC Criteria

January 27, 2026

First Posted (Actual)

February 3, 2026

Study Record Updates

Last Update Posted (Actual)

February 3, 2026

Last Update Submitted That Met QC Criteria

January 27, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2025004A

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe